Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Mar 23, 2023
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
Mar 21, 2023
Mar 16, 2023
Mar 28 - Apr 1, 2023
Mar 23, 2023 at 8:00 AM EDT
Mar 15, 2023 at 10:00 AM EDT
Latest SEC Filings
Report of unscheduled material events or corporate event
Annual report which provides a comprehensive overview of the company for the past year
Securities offered to employees pursuant to employee benefit plans